Saturday, October 12, 2019 • 7:00 PM
New York Academy of Medicine, 1216 5th Ave, New York, NY 10029
On Saturday, October 12, 2019, you’re invited to join MAPS for our 8th annual benefit dinner in New York City at the New York Academy of Medicine. We are thrilled to host special guests Hamilton Morris from VICE TV’s “Hamilton’s Pharmacopeia,” Dr. Rachel Yehuda from Icahn School of Medicine at Mount Sinai, MAPS-sponsored Phase 2 MDMA therapist Will Van Derveer, M.D., and MAPS Founder Rick Doblin, Ph.D.
More tickets are now available!
Due to a change in our event venue, additional tickets are now available for purchase. Be sure to reserve your seat at the table today!
This fundraising event supports the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. We are continuously grateful for the opportunity to connect with MAPS supporters in New York, and we would like to share a special honoring of Doug Greene, who passed away this past year. Doug was one of our first major donors in New York City and provided strong support for research with ibogaine therapy as a treatment for addiction.
Rachel Yehuda, Ph.D.
Rachel Yehuda, Ph.D., is a Professor and Vice Chair of Psychiatry, and Professor of Neuroscience at the Icahn School of Medicine at Mount Sinai. She is also the Mental Health Patient Care Center Director at the Bronx Veterans Affairs. She has published several hundred scientific papers and compiled over 10 books examining diverse aspects of traumatic stress, and has studied PTSD and resilience in combat veterans, survivors of genocide, interpersonal violence and terrorism, as well as in animal models. Her work has focused on neuroendocrinology, neuroimaging, genomic and molecular biological studies of trauma, experimental therapeutics (pharmacological and psychotherapy trials), biomarkers, genetic and epigenetic heritability, gender differences, and suicide.
Rick Doblin, Ph.D.
Rick Doblin, Ph.D., is Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife, two dogs, and empty rooms from three children, one of whom is in college and two have graduated.
Will Van Derveer, M.D.
Will Van Derveer, M.D., is a psychiatrist and psychotherapist with several years of experience participating in indigenous shamanic medicine ceremonies abroad. He has facilitated integration for retreat participants during and after retreats with Gabor Mate M.D. Dr. Van Derveer is a study physician and psychotherapist on multiple MAPS clinical trials, evaluating MDMA-assisted psychotherapy for PTSD. In this context, he has provided study subjects preparation and integration sessions as well as MDMA psychotherapy. He has practiced integrative psychiatry in Boulder, Colorado, since 2002, and teaches psychiatric providers and psychiatry trainees how to heal people without relying solely on medications.
Hamilton Morris is a scientist and filmmaker. His television series Hamilton’s Pharmacopeia investigates the chemistry, history, and culture surrounding various psychoactive drugs. Hamilton Morris was born in New York City, the son of Julia Sheehan and documentary filmmaker Errol Morris. He was raised in Cambridge, Massachusetts. As a teenager, Morris appeared in television commercials, notably a 2002 advertisement for the first-generation iPod. He attended the University of Chicago and The New School, where he studied anthropology and science. He began writing for Vice Magazine as a college sophomore and was given a monthly print column titled “Hamilton’s Pharmacopeia” that evolved into a series of articles and documentaries for VBS.tv focused on the science of psychoactive drugs. He is a science editor of Vice Magazine and a correspondent for Vice (TV series) on HBO, as well as a regular science columnist for Harper’s Magazine. Morris frequently consults with media on the subject of psychoactive drugs and conducts pharmacological research at the University of the Sciences in Philadelphia with an emphasis on the synthesis and history of dissociative anesthetics.
Special thanks to our lead hosts, Giancarlo and Stephanie Canavesio, and also to our host committee (in formation):
- Susan Brody
- Michael Brotherton
- Sheila Burgel
- Alisa Cohn
- Stefanie Frank and Gordon Kindlon
- Anthony Hidalgo and Lauren Mazukiewicz
- Michael Pollack
- Ethan Ruby and Julie Ruby
- Deborah Starr, Ph.D.
- Monica Winsor and Josh Mailman
Thank you to Dr. Bronner’s for their company’s support of this event!
Please send any questions to email@example.com
This event coincides with the 13th annual Horizons: Perspectives on Psychedelics conference in New York City, taking place from October 10-14, 2019.
Horizons is an opportunity to explore the role of psychedelic medicines in science, healing, culture, and spirituality. Learn more about MAPS’ research during Horizons at the MAPS table or during conference talks from Charlotte Harrison, MAPS Public Benefit Corporation (MAPS PBC) Clinic Trial Leader, who will be presenting recent updates about Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD. Ismail Ali, J.D., MAPS Policy and Advocacy Counsel, will speak during the conference about challenges and opportunities of decriminalizing psychedelics. Horizons is also hosting a workshop on MDMA therapy for clinicians, which will be led by Shannon Clare Carlin, M.A., A.M.F.T., MAPS Public Benefit Corporation (MAPS PBC) Director of Training and Supervision, and MAPS-sponsored researcher Marcela Ot’alora, M.F.A., M.A., L.P.C.
Thank you to Dr. Bronner’s for supporting this event!